Zacks.com on MSN47m
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion ...
The Associated Press on MSN5m
Don't wait for a holiday surge. Now is a good time to get your flu and COVID-19 vaccines
Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to ...
Investor's Business Daily on MSN24m
Moderna Surges After Crushing Sales Forecasts, Reiterating Its Outlook
Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit. But Moderna stock pulled back ...
The Globe and Mail5m
These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over
Meanwhile, investors are getting impatient for Moderna's next triumph after its Spikevax became a go-to vaccine during the COVID-19 pandemic's height. Of the quintet, the only stock I think might be a ...
The Globe and Mail43m
Stocks Extend Post-Election Gains Ahead of the FOMC Meeting
Moderna (MRNA) is up more than +3% after reporting Q3 Covid-19 vaccine revenue of $1.8 billion, which is stronger than the consensus of $1.2 billion. Lyft (LYFT) is up more than +29% after reporting ...
Yahoo Finance24m
Stock market today: S&P 500, Nasdaq hit records as Fed cuts rates, post-election rally rolls on
Hershey: Adjusted earnings per share of $2.34 vs. $2.56 per share expected, revenue of $2.99 billion vs. $3.07 billion expected Moderna: Earnings per share of $0.03 vs. a loss of $1.98 per share ...